Our mission is to deliver transformational therapies for solid tumors and I&I diseases in the form of multifunctional antibodies that create immune synapses to precisely activate or inhibit T cells. We have a world class team with a proven track record of success, which positions us well to advance the next generation of highly innovative medicines that redefine the standard-of-care.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Peter Lebowitz

Chief Operating Officer

Joseph Erhardt

Chief Scientific Officer

Sanjaya Singh

VP - Bus. Development

Debi Watson

Browse more venture capital transactions:

Prev: 7/23/2024: Level AI venture capital transaction
Next: 7/23/2024: Farmblox venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary